NextCure
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 82
- Market Cap
- -
- Website
- http://www.nextcure.com
- Introduction
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.
A Safety, Tolerability and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT05787496
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT05572684
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸St. Elizabeth Edgewood Hospital, Edgewood, Kentucky, United States
A Safety and Tolerability Study of NC762 in Subjects with Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-05-06
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT04875806
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- NextCure, Inc.
- Registration Number
- NCT04430933
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04408599
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸NIH National Cancer Institute (NCI), Bethesda, Maryland, United States
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- NextCure, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT03665285
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸NEXT Oncology, San Antonio, Texas, United States